Results 61 to 70 of about 17,579 (227)

Safety and Effectiveness of Glecaprevir/Pibrentasvir in Children and Adolescents With Chronic Hepatitis C: Reports From All‐Case Post‐Marketing Surveillance in Japan

Hepatology Research, EarlyView.
ABSTRACT Aim The aim of this all‐case post‐marketing study was to evaluate the real‐world safety and effectiveness in all children and adolescents with chronic hepatitis C with or without compensated cirrhosis treated with glecaprevir/pibrentasvir (G/P) in Japan. Methods This prospective, observational post‐marketing surveillance study was conducted at
Tatsuki Mizuochi, Katsuyoshi Kawana, Mariko Kobayashi, Eri Iwashita, Itaru Iwama, Daiki Abukawa, Hitoshi Tajiri   +6 more
wiley   +1 more source

GPS2 is required for the association of NS5A with VAP-A and hepatitis C virus replication.

PLoS ONE, 2013
Hepatitis C virus (HCV) nonstructural protein 5A (NS5A) is a component of the replication complex associated with various cellular proteins. It has been reported that G protein pathway suppressor 2 (GPS2) is a potential NS5A-binding factor, as identified
Guodong Xu, Xiu Xin, Congyi Zheng
doaj   +1 more source

Timing for treatment of HCV recurrence after liver transplantation: the earlier the better. [PDF]

, 2016
HCV is the leading cause of death from liver disease and is the most common indication for a liver transplantation. Although HCV is a widespread health problem, disease management is particularly challenging in several key subpopulations, including liver
Burra, Patrizia, Russo, Francesco Paolo, Zanetto, A   +2 more
core   +1 more source

Synthesis and evaluation of non-dimeric HCV NS5A inhibitors [PDF]

Bioorganic & Medicinal Chemistry Letters, 2013
Based on the symmetrical bidentate structure of the NS5A inhibitor BMS-790052, a series of new monodentate molecules were designed. The synthesis of 36 new non-dimeric NS5A inhibitors is reported along with their ability to block HCV replication in an HCV 1b replicon system. Among them compound 5a showed picomolar range activity along with an excellent
Franck, Amblard, Hongwang, Zhang, Longhu, Zhou, Junxing, Shi, Drew R, Bobeck, James H, Nettles, Satish, Chavre, Tamara R, McBrayer, Philip, Tharnish, Tony, Whitaker, Steven J, Coats, Raymond F, Schinazi   +11 more
openaire   +2 more sources

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against hepatitis C virus. In vitro studies assessing the inhibition or induction potential of bemnifosbuvir on the CYP450 and UGT1A1 enzymes demonstrated that bemnifosbuvir is a weak inducer and a reversible and time‐dependent inhibitor of
Xiao‐Jian Zhou, Alex Vo, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Steven Good, Arantxa Horga, Nancy Agrawal, Janet Hammond   +10 more
wiley   +1 more source

Phosphorylation of Serine 235 of the Hepatitis C Virus Non-Structural Protein NS5A by Multiple Kinases.

PLoS ONE, 2016
Phosphorylation at serine 235 (S235) of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) plays a critical role in the viral life cycle. For medical and virological interests, we exploited the HEK293T kidney cells to test 3 candidate protein ...
Kuan-Ying Lee, Yi-Hung Chen, Shih-Chin Hsu, Ming-Jiun Yu   +3 more
doaj   +1 more source

Phytochemical analysis of Berberis lyceum methanolic extract and its antiviral activity through the restoration of MAPK signaling pathway modulated by HCV NS5A

Asian Pacific Journal of Tropical Biomedicine, 2021
Objective: To evaluate the antiviral activity and phytochemicals of selected plant extracts and their effect on the mitogen-activated protein kinase (MAPK) signaling pathway modulated by hepatitis C virus (HCV) nonstructural protein 5A (NS5A). Methods: A
Koloko Brice Landry, Shafiq Azam, Sidra Rehman, Somayya Tariq, Bushra Iqbal, Mateen Abbas, Dieudonné Massoma Lembè, Bushra Ijaz   +7 more
doaj   +1 more source

Microbial translocation and T cell activation are modified by direct-acting antiviral therapy in HCV-infected patients [PDF]

, 2018
BACKGROUND: Microbial translocation from the gut lumen has been involved in the pathogenesis of liver damage in hepatitis C virus (HCV) infection. AIM: To investigate the impact of direct-acting antiviral treatment on microbial translocation and T ...
Baroncelli, Silvia, DE SANTIS, Adriano, GINANNI CORRADINI, Stefano, Lattanzi, Barbara, Lupo1, Marinella, Maria Galluzzo, Clementina, Mennini, Gianluca, Merli, Manuela, Michelini, Zuleika, Palmisano, Lucia, Rossi, Massimo   +10 more
core   +1 more source

Diacylglycerol Acyltransferase-1 Localizes Hepatitis C Virus NS5A Protein to Lipid Droplets and Enhances NS5A Interaction with the Viral Capsid Core [PDF]

Journal of Biological Chemistry, 2013
The triglyceride-synthesizing enzyme acyl CoA:diacylglycerol acyltransferase 1 (DGAT1) plays a critical role in hepatitis C virus (HCV) infection by recruiting the HCV capsid protein core onto the surface of cellular lipid droplets (LDs). Here we find a new interaction between the non-structural protein NS5A and DGAT1 and show that the trafficking of ...
Camus, Gregory, Herker, Eva, Modi, Ankit A, Haas, Joel T, Ramage, Holly R, Farese, Robert V, Ott, Melanie   +6 more
openaire   +4 more sources

Vaccines at the Heart of Hepatitis Elimination: Insights From the ESCMID Study Group for Viral Hepatitis (ESGVH)

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT The global elimination of viral hepatitis by 2030 remains an ambitious goal that hinges not only on diagnostics and therapeutics but fundamentally on the strategic use and continued innovation of vaccines. The ESCMID Study Group for Viral Hepatitis (ESGVH) convened to examine the role of vaccination as the cornerstone of hepatitis prevention ...
Oana Săndulescu, Gülşen Özkaya Şahin, Susanne Gjeruldsen Dudman, Zeinab Nabil Ahmed Said, Mario U. Mondelli, on behalf of ESCMID Study Group for Viral Hepatitis (ESGVH)   +5 more
wiley   +1 more source